http://orcid.org/0000-0001-7295-0978
References
- Giroux Leprieur E, Dumenil C, Julie C, et al. Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges. Eur J Cancer. 2017;78:16–23.
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
- Socinski M, Creelan B, Horn L, et al. NSCLC, metastatic CheckMate 026: a phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC. Ann Oncol [Internet]. 2016;27. [cited 2017 Jul 7]. Available from: https://academic.oup.com/annonc/article-abstract/27/suppl_6/LBA7_PR/2800548/NSCLC-metastaticCheckMate-026-A-phase-3-trial-of
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
- Scheuplein F, Ranganath S, Feng B, et al. Abstract 4871: two novel anti-PD-1 antibodies, 244C8 and 388D4, elicit in vivo antitumor efficacy in a lung PDX tumor graft in immuno-humanized NSG mice. Cancer Res. 2016;76:4871–4871.
- Naing A, Gelderblom H, Gainor JF, et al. A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors. J Clin Oncol. 2016;34:3060–3060.
- A study of FAZ053 single agent and in combination with PDR001 in patients with advanced malignancies. - Full Text View - ClinicalTrials.gov [Internet]. [cited 2017 Jul 5]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02936102
- Papadopoulos KP, Crittenden MR, Johnson ML, et al. A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT). J Clin Oncol. 2016;34:3024–3024.
- Study of REGN 2810 compared to platinum-based chemotherapies in participants with metastatic non-small cell lung cancer (NSCLC) – full text view – ClinicalTrials.gov [Internet]. [cited 2017 Jul]. Available from: https://clinicaltrials.gov/ct2/show/NCT03088540
- A phase 1/2, open-label study to evaluate the safety and antitumor activity of MEDI0680 (AMP-514) in combination with durvalumab versus nivolumab monotherapy in subjects with select advanced malignancies – full text view – ClinicalTrials.gov [Internet]. [cited 2017 Jul 6]. Available from: https://clinicaltrials.gov/show/NCT02118337
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
- Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. Jama. 2016;315:1600.
- Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16:121–126.
- Lee JY, Lee HT, Shin W, et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun. 2016;7:ncomms13354.